Company Encyclopedia
View More
name
Staidson BioPharm
300204.SZ
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release tablets, Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C.
1.556 T
300204.SZMarket value -Rank by Market Cap -/-

Financial Score

27/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking66/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-17.46%E
    • Profit Margin-68.00%E
    • Gross Margin79.56%A
  • Growth ScoreD
    • Revenue YoY-30.32%E
    • Net Profit YoY25.58%B
    • Total Assets YoY-1.57%D
    • Net Assets YoY-16.77%E
  • Cash ScoreE
    • Cash Flow Margin-147.06%D
    • OCF YoY-30.32%E
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreB
    • Gearing Ratio31.98%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "A-Share Focus" Staidson BioPharm plummets 8.5%, the third-largest shareholder plans to reduce holdings

    Pharmaceutical company Staidson BioPharm (Shenzhen: 300204) saw its stock price plummet by 8.5%, currently reported at 34.02 yuan. The company announced that its third-largest shareholder, Xiangtang Group, plans to reduce its holdings by no more than 4.7777 million shares, accounting for 1% of the total share capital. Based on yesterday's closing price, the cash amount that Xiangtang Group will realize is approximately 178 million yuan. Xiangtang Group currently holds 27.1396 million shares, accounting for 5.68% of the total share capital. This year, Staidson's stock price has increased by 361%

    etnet·
    SZ
    300204
    +2.02%
    etnet·
    SZ
    300204
    +2.02%

    Staidson BioPharm today hit a 20% limit up, with 5 institutional special seats net buying 229 million yuan

    Staidson BioPharm today hit a 20% limit up, with a transaction amount of 2.427 billion yuan and a turnover rate of 15.01%. According to the after-hours dragon and tiger list data, 5 institutional special seats net bought 229 million yuan, while 1 institutional special seat net sold 30.9812 million yuan

    Zhitong·
    SZ
    300204
    +2.02%
    Zhitong·
    SZ
    300204
    +2.02%

    Staidson BioPharm released its performance for the first three quarters, with a net loss attributable to the parent company of 30.6895 million yuan

    According to the Zhitong Finance APP, Staidson BioPharm released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 181 million yuan, a year-on-year decrease of 30.82%. The net loss attributable to shareholders of the listed company was 30.6895 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 34.3569 million yuan. The basic loss per share was 0.06 yuan

    Zhitong·
    SZ
    300204
    +2.02%
    Zhitong·
    SZ
    300204
    +2.02%

    Staidson BioPharm: Application for stock issuance to specific objects accepted by Shenzhen Stock Exchange

    Staidson BioPharm announced that on October 24, 2025, the company received a notice from the Shenzhen Stock Exchange stating that its application documents for issuing shares to specific targets have been accepted. This issuance still needs to be approved by the Shenzhen Stock Exchange and obtain the registration decision from the China Securities Regulatory Commission before it can be implemented. There is uncertainty regarding whether it will pass the review and the timeline, and the company will disclose progress in a timely manner

    Zhitong·
    SZ
    300204
    +2.02%
    Zhitong·
    SZ
    300204
    +2.02%

    Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up

    Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up, Shen Lian Biomedical, Staidson BioPharm, CISEN, and WECOME follow suit

    Zhitong·
    SZ
    300683
    -0.73%
    SZ
    002004
    +0.21%
    SH
    688098
    -0.67%
    Zhitong·
    SZ
    300683
    -0.73%
    SZ
    002004
    +0.21%
    SH
    688098
    -0.67%
    © 2025 Longbridge｜Disclaimer